Specificity testing by point prevalence as a simple assessment strategy using the Roche Elecsys(R) Anti-SARS-CoV-2 immunoassay.
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgA, IgM
Testing Method Category
Other Immuno assay
Testing Method
e Roche Elecsys Anti-SARS-CoV2
Testing Method - Additional Info
strategy for validation and performance verification of serological assays without biobanking and standard clinical samples
Reported Performance
Specificty: 99.84% ; NPV: 99.98%
Sample Size
627 patients
Peer-reviewed
yes
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements